Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2020

01-04-2020 | NSCLC | AdisInsight Report

Trastuzumab Deruxtecan: First Approval

Author: Susan J. Keam

Published in: Drugs | Issue 5/2020

Login to get access

Abstract

Trastuzumab deruxtecan (ENHERTU®), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval.
Literature
1.
2.
Daiichi Sankyo Company Ltd, AstraZeneca. Daiichi Sankyo and AstraZeneca announce global development and commercialization collaboration for Daiichi Sankyo’s HER2 targeting antibody drug conjugate [fam-] trastuzumab deruxtecan (DS-8201) [media release]. 29 Mar 2019. http://​www.​daiichisankyo.​com.
3.
4.
Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173–85.CrossRef
5.
Daiichi Sankyo Company Ltd. Daiichi Sankyo advances [fam-] trastuzumab deruxtecan (DS-8201) in Japan with regulatory submission in HER2 positive metastatic breast cancer [media release]. 9 Sep 2019. http://​www.​daiichisankyo.​com.
6.
7.
Daiichi Sankyo Company Ltd. Daiichi Sankyo announces clinical research collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate [fam-] trastuzumab deruxtecan (DS-8201) with avelumab and a DNA damage response inhibitor in patients with HER2 expressing and mutate [media release]. 25 Oct 2018. http://​www.​daiichisankyo.​com.
8.
Daiichi Sankyo Company Ltd, Puma Biotechnology Inc. Daiichi Sankyo and Puma Biotechnology announce research collaboration with major cancer center in HER2-mutated cancer [media release]. 12 Dec 2017. https://​www.​daiichisankyo.​com/​.
9.
Bristol-Myers Squibb, Daiichi Sankyo Company Ltd. Bristol-Myers Squibb and Daiichi Sankyo announce research collaboration to evaluate Opdivo® (nivolumab) and DS-8201 in HER2-expressing breast and bladder cancers [media release]. 28 Aug 2017. http://​www.​bms.​com.
10.
Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–46.CrossRef
11.
Takegawa N, Tsurutani J, Kawakami H, et al. fam- Trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer. 2019;145(12):3414–24.CrossRef
12.
Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I Inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108.CrossRef
13.
Takegawa N, Nonagase Y, Yonesaka K, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141(8):1682–9.CrossRef
14.
Yamashita T, Shimomura A, Takano O, et al. A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer [abstract no. P1-18-12]. In: San Antonio Breast Cancer Symposium. 2019.
15.
Bang YJ, Karayama M, Takahashi M, et al. Pharmacokinetics (PK), safety, and efficacy of [fam]-trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumours [abstract no. 330P]. Ann Oncol. 2019;30(Suppl 5):v116–7.CrossRef
16.
17.
Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816–26.CrossRef
18.
Modi S, Tsurutani J, Tamura K, et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: updated results of a large phase 1 study [abstract no. P6-17-02 plus poster]. Cancer Res. 2018;79(4 Suppl):6–17.
19.
20.
Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a)in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):827–36.CrossRef
21.
Tsurutani J, Park H, Doi T, et al. Updated results of phase 1 study of DS-8201a in HER2-expressing or -mutated advanced non-small-cell lung cancer [abstract no. OA02.07]. J Thorac Oncol. 2018;13(10 Suppl):S324.CrossRef
22.
Daiichi Sankyo Company Ltd. Daiichi Sankyo presents updated results for [fam-] trastuzumab deruxtecan (DS-8201) in patients with HER2 mutated or HER2 expressing non-small cell lung cancer at IASLC 19th World Conference on Lung Cancer [media release]. 24 Sep 2018. http://​www.​daiichisankyo.​com.
23.
Yoshino T, Iwata H, Tamura K, et al. Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer [abstract no. 563P]. Ann Oncol. 2018;29(Suppl 8):viii188.CrossRef
24.
Daiichi Sankyo Company Ltd. Daiichi Sankyo presents updated results of [fam-] trastuzumab deruxtecan (DS-8201) in patients with HER2 expressing advanced colorectal cancer at 2018 European Society for Medical Oncology (ESMO) congress [media release]. 22 Oct 2018. http://​www.​daiichisankyo.​com.
25.
US Food and Drug Administration. FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies [media release]. 7 Jan 2019. https://​www.​fda.​gov/​.
26.
Metadata
Title
Trastuzumab Deruxtecan: First Approval
Author
Susan J. Keam
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2020
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-020-01281-4

Other articles of this Issue 5/2020

Drugs 5/2020 Go to the issue

Leading Article

TSLP Inhibitors for Asthma: Current Status and Future Prospects

Original Research Article

Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study

AdisInsight Report

Tazemetostat: First Approval

Leading Article

Mechanisms of Resistance to PD-1 Checkpoint Blockade

AdisInsight Report

Teprotumumab: First Approval

Adis Drug Evaluation

Cenegermin: A Review in Neurotrophic Keratitis